In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—

Drug Development Lessons for 2026 Drawn from 2025 Realities, Upcoming Webinar Hosted by Xtalks

2026/02/18 21:46
3 min read

In this free webinar, gain executive-level takeaways in drug development to sharpen 2026 decisions. Attendees will learn what actually moved the needle in 2025—and what quietly stalled. The featured speakers will share insights into smart AI adoption, including how to scale innovation with confidence, not chaos. The speakers will also discuss sponsor-CRO partnership dynamics, involving what changed in 2025, where friction shows up, and how high-performing teams clarify roles, decisions, and accountability early. Attendees will learn how leaders navigate shifting priorities, resourcing, and assumptions without compromising timelines or quality. The speakers will also share when connected partners accelerate outcomes—and when handoffs, systems, and workflows introduce avoidable drag. Attendees can expect candid lessons, real trade-offs, and a few myths challenged.

TORONTO, Feb. 18, 2026 /PRNewswire/ — Over the past year, “progress” in drug development started to look very different. AI moved beyond pilots into day-to-day execution, while protocols, regulatory expectations, and budgets grew more complex. The mandate to accelerate only intensified—and so did the pressure on sponsor-CRO partnerships to deliver with clarity and confidence.

So what actually worked in 2025—and what didn’t?

Join an executive fireside chat with leaders from Thermo Fisher Scientific and the PPD™ clinical research business of Thermo Fisher Scientific for a candid, lessons-learned conversation grounded in real-world delivery. Hear what teams discovered in execution — not theory — and how those insights are shaping 2026 plans in an environment where uncertainty is the new baseline.

You’ll walk away with practical takeaways on:

  • Where AI and digital workflows delivered real impact, where adoption stalled, and how to scale responsibly
  • How CRO partnership dynamics changed—what’s driving friction, what “good” looks like now, and how to reset ways of working
  • How to navigate shifting priorities and constraints without compromising timelines or quality
  • How to reduce integration pitfalls across systems, vendors, and workflows to build a more resilient operating model

Bring your questions and join the conversation live. Register now to turn 2025 learnings into smarter, faster, more confident decisions for 2026.

Join Krishna Cheriath, Vice President, Head of Digital and AI, BioPharma Services, Thermo Fisher Scientific; Mike Kleppinger, President, Commercial Operations, the PPD clinical research business of Thermo Fisher Scientific; Brenda Bruker, Executive Director, Clinical Development Strategy & Innovation, Clinical Research Group, Thermo Fisher Scientific; and Guzel Adams (Moderator), Customer Insights & Strategy Director, the PPD clinical research business of Thermo Fisher Scientific, for the live webinar on Tuesday, March 10, 2026, at 11am EDT (4pm CET/EU-Central).

For more information, or to register for this event, visit Drug Development Lessons for 2026 Drawn from 2025 Realities.

Xtalks — The Life Science Community™ empowers professionals across pharma, biotech, medtech, healthcare and research with the trusted knowledge and collaborative insights that move the industry forward. Powered by Honeycomb Worldwide Inc., Xtalks delivers news, feature articles, webinars, podcasts, videos, expert interviews, curated job opportunities and more designed to support informed decision-making in a fast-evolving sector.

Every year, thousands of professionals rely on Xtalks for timely intelligence, peer perspectives and industry thought leadership. Join our life science community to stay informed, connected and ready for what’s next.

To learn more about Xtalks, visit www.xtalks.com

For information about working with Xtalks to host your webinar, visit https://xtalks.com/partner-with-us/

Media Contact: Vera Kovacevic Tel: +1 (416) 977-6555 x371 Email: [email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/drug-development-lessons-for-2026-drawn-from-2025-realities-upcoming-webinar-hosted-by-xtalks-302691171.html

SOURCE Xtalks

Market Opportunity
Cronos Logo
Cronos Price(CRO)
$0.07936
$0.07936$0.07936
-0.33%
USD
Cronos (CRO) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact [email protected] for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.
Tags:

You May Also Like

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

Trump adviser demands Fed economists be 'disciplined' for arguing with presidential tactic

President Donald Trump's longtime economic adviser Kevin Hassett suggested on CNBC Wednesday that the economists at the New York Fed who produced an analysis revealing
Share
Rawstory2026/02/18 22:59
Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

Trump admin appeals after judge orders slavery exhibit returned to Philadelphia museum

President Donald Trump's Department of the Interior and its secretary, Doug Burgum, have appealed after Judge Cynthia Rufe invoked George Orwell's dystopian novel
Share
Rawstory2026/02/18 23:24
BlackRock boosts AI and US equity exposure in $185 billion models

BlackRock boosts AI and US equity exposure in $185 billion models

The post BlackRock boosts AI and US equity exposure in $185 billion models appeared on BitcoinEthereumNews.com. BlackRock is steering $185 billion worth of model portfolios deeper into US stocks and artificial intelligence. The decision came this week as the asset manager adjusted its entire model suite, increasing its equity allocation and dumping exposure to international developed markets. The firm now sits 2% overweight on stocks, after money moved between several of its biggest exchange-traded funds. This wasn’t a slow shuffle. Billions flowed across multiple ETFs on Tuesday as BlackRock executed the realignment. The iShares S&P 100 ETF (OEF) alone brought in $3.4 billion, the largest single-day haul in its history. The iShares Core S&P 500 ETF (IVV) collected $2.3 billion, while the iShares US Equity Factor Rotation Active ETF (DYNF) added nearly $2 billion. The rebalancing triggered swift inflows and outflows that realigned investor exposure on the back of performance data and macroeconomic outlooks. BlackRock raises equities on strong US earnings The model updates come as BlackRock backs the rally in American stocks, fueled by strong earnings and optimism around rate cuts. In an investment letter obtained by Bloomberg, the firm said US companies have delivered 11% earnings growth since the third quarter of 2024. Meanwhile, earnings across other developed markets barely touched 2%. That gap helped push the decision to drop international holdings in favor of American ones. Michael Gates, lead portfolio manager for BlackRock’s Target Allocation ETF model portfolio suite, said the US market is the only one showing consistency in sales growth, profit delivery, and revisions in analyst forecasts. “The US equity market continues to stand alone in terms of earnings delivery, sales growth and sustainable trends in analyst estimates and revisions,” Michael wrote. He added that non-US developed markets lagged far behind, especially when it came to sales. This week’s changes reflect that position. The move was made ahead of the Federal…
Share
BitcoinEthereumNews2025/09/18 01:44